

DAFTAR PUSTAKA

1. Paul D. The systemic hallmarks of cancer. *J Cancer Metastasis Treat*. 2020 Aug 28;6:29.
2. Deo SVS, Sharma J, Kumar S. GLOBOCAN 2020 report on global cancer burden: challenges and opportunities for surgical oncologists. *Ann Surg Oncol*. 2022 Oct 15;29(11):6497–500.
3. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Health*. 2019 Apr;11:287–99.
4. The Global Cancer Observatory (Globocan). Indonesia [Internet]. 2020 [cited 2023 Mar 26]. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>
5. The Global Cancer Observatory (Globocan). Estimated number of new cases in 2020, all ages (excl. NMSC) [Internet]. *Cancer Today*. 2020 [cited 2023 Oct 15]. Available from: <https://gco.iarc.fr/today/fact-sheets-populations>
6. Nabilla M. Hubungan *skor risk malignancy index* dengan stadium kanker ovarium tipe epitel di RSUP Dr. Djamil Padang [Skripsi]. [Padang]: Universitas Andalas; 2021.
7. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. *Semin Oncol Nurs*. 2019 Apr;35(2):151–6.
8. Upadhyay A, Garg V, Mathur S, Singh Malik P, Bhatla N, Kumar S, et al. Early-Stage epithelial ovarian cancer: predictors of survival. *Gynecol Oncol Rep*. 2022 Dec;44:101083.
9. Oktovina M. Penggunaan sitostatika pada pasien kanker dewasa di ruang kemoterapi RSUP Fatmawati periode bulan Januari sampai Juni tahun 2020. *Jurnal Farmasi Klinik Base Practice*. 2022 Dec 10;1(1):14–28.
10. Altun i, Sonkaya A. The most common side effects experienced by patients were receiving first cycle of chemotherapy. *Iran J Public Health*. 2018 Aug;47(8):1218–9.
11. Vaid AK, Gupta S, Doval DC, Agarwal S, Nag S, Patil P, et al. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. *Front Oncol*. 2020 Mar 27;10.
12. J. Wickham PRR. Nausea and vomiting not related to cancer therapy: intractable problem or clinical challenge? *J Adv Pract Oncol*. 2020 Jul 1;11(5).

13. Komatsu H, Oishi T, Sato S, Osaku D, Sawada M, Kudoh A, et al. Evaluating chemotherapy-induced nausea and vomiting and food intake in patients with gynecologic cancer. *Anticancer Res.* 2019 Aug 31;39(8):4555–60.
14. Farlex. Emetogenic [Internet]. The Free Dictionary. 2023 [cited 2023 Oct 15]. Available from: <https://medical-dictionary.thefreedictionary.com/emetogenic>
15. Leksuwankun S, Wonganan P. Chemotherapy-induced nausea and vomiting. *Thai Journal of Pharmacology.* 2020 Dec 19;42(2):23–36.
16. National Cancer Institute at National Institutes of Health. Nausea and vomiting related to cancer treatment (pdq®) – health professional version [Internet]. 2023 [cited 2024 Mar 5]. Available from: https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq#section_5.4
17. Al-Salloum HF, AL-Harbi HE, Abdelazeem A. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; an oncology center experience. *Journal of Oncology Pharmacy Practice.* 2022 Dec 14;
18. Oldak S, Ioannou S, Kamath P, Huang M, George S, Slomovitz B, et al. Polypharmacy in patients with ovarian cancer. *Oncologist.* 2019 Sep 1;24(9):1201–8.
19. Mekonnen BD, Ayalew MZ, Tegegn AA. Rational drug use evaluation based on world health organization core drug use indicators in Ethiopia: a systematic review. *Drug Healthc Patient Saf.* 2021 Jul;13:159–70.
20. Fakhriani. Perbandingan respon kemoterapi platinum pada kanker ovarium epitelial tipe serosum dengan musinosum di RSUP Dr. M. Djamil Padang [Skripsi]. Universitas Andalas; 2021.
21. Ningsih NC. Perbedaan tingkat ansietas dan dukungan keluarga pasien kanker serviks dengan pasien kanker ovarium stadium lanjut di RSUP Dr. M. Djamil Padang tahun 2020 [Skripsi]. Universitas Andalas; 2021.
22. Sepriani M. Asuhan keperawatan pada ny. a (30 tahun) dengan kanker ovarium stadium ii b + anemia sedang dan penerapan *evidence based nursing practice* relaksasi nafas dalam dan distraksi dengan latihan lima jari di ruangan ginekologi onkologi RSUP Dr. M. Djamil Padang [Skripsi]. Universitas Andalas; 2019.
23. Sutarmanto E. Identifikasi *adverse drug reaction* dan efektivitas penanganan mual-muntah pada pasien kanker ovarium di RSUD Dr. Moewardi Surakarta [Tesis]. Universitas Muhammadiyah Surakarta; 2020.
24. McKinley M, O’Loughlin V, Pennefather-O’Brien E. *Human anatomy.* 6th ed. Vol. 6. New York: McGraw Hill; 2020.

25. Hallas-Potts A, Dawson JC, Herrington CS. Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. *Sci Rep.* 2019 Apr 2;9(1):5515.
26. Dinneen K, Arora R. Molecular testing in ovarian tumours: challenges from the pathologist's perspective. *Diagnostics.* 2023 Jun 15;13(12):2072.
27. Hayashi T, Konishi I. Molecular histopathology for establishing diagnostic method and clinical therapy for ovarian carcinoma. *J Clin Med Res.* 2023 Feb;15(2):68–75.
28. Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. *Cureus.* 2022 Oct 21;14(10):e30561.
29. Kurnit K, Westin SN, Salani R. Epithelial ovarian cancer. In: Creasman WT, Mannel RS, Mutch DG, Tewari K, editors. *Disaia and Creasman Clinical Gynecology Oncology.* 10th ed. Elsevier; 2023. p. 255–61.
30. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: pathogenesis and current recommendations for prophylactic surgery. *Journal of the Turkish-German Gynecological Association.* 2019 Mar 1;20(1):47–54.
31. Zayyan MS. Risk factors for ovarian cancer. In: *Tumor Progression and Metastasis.* IntechOpen; 2020. p. 1–27.
32. Ali AT, Al-ani O, Al-ani F. Epidemiology and risk factors for ovarian cancer. *Menopausal Review.* 2023 Feb;22(2):93–104.
33. Handoko AL, Jayadi T, Putra ERK, Kusumosih TAR. Hubungan antara obesitas dengan kanker ovarium di Rumah Sakit Bethesda Yogyakarta. *Jurnal Kedokteran Meditek.* 2023 Jan 14;29(1):27–33.
34. Zhong W, Wang X, Wang Y, Sun G, Zhang J, Li Z. Obesity and endocrine-related cancer: the important role of IGF-1. *Front Endocrinol (Lausanne).* 2023 Jan 23;14:1093257.
35. St.Fatimah StF, Latief S, Syahrudin FI, Nulanda M, Mokhtar S. Faktor risiko penderita kanker ovarium di Rumah Sakit Ibnu Sina Makassar. *Wal'afiat Hospital Journal.* 2023 Jun 27;4(1):46–56.
36. Nababan EHF, Sihotang J, Sasputra IN, Damanik EMB. Faktor risiko kanker ovarium jenis epitelial Di RSUD Prof. Dr.W.Z Johannes Kota Kupang Nusa Tenggara Timur tahun 2016-2019. *Cendana Medical Journal (CMJ).* 2021 Nov 1;9(2):198–206.
37. Xia YY, Kotsopoulos J. Beyond the pill: contraception and the prevention of hereditary ovarian cancer. *Hered Cancer Clin Pract.* 2022 Dec 6;20(1):21.

38. Tashiro H, Imamura Y, Motohara T, Sakaguchi I, Katabuchi H. Morphological and molecular pathogenesis of epithelial ovarian tumors. In: Katabuchi H, editor. *Frontiers in Ovarian Science*. Singapore: Springer; 2017. p. 37–56.
39. Marindawati M, Ferdiana F, Sugiarto S, Nadhif A. Analisis karakteristik kliniko-histopatologi pasien kanker ovarium di Rumah Sakit Umum Daerah Cengkareng Jakarta Barat tahun 2016-2021. *Muhammadiyah Journal of Midwifery*. 2023 Jun 28;4(1):1.
40. Harsono AB. Kanker ovarium: “*the silent killer*”. *Indonesian Journal of Obstetrics & Gynecology Science*. 2020 Mar;3(1).
41. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: a comprehensive review. *Cancers (Basel)*. 2020 Dec 11;12(12):3730.
42. Vlasak P, Bouda J, Kostun J, Berezovskiy D, Zikan M, Weinberger V, et al. Diagnostic reliability, accuracy and safety of ultrasound-guided biopsy and ascites puncture in primarily inoperable ovarian tumours. *Anticancer Res*. 2020 Jun 2;40(6):3527–34.
43. Sambasivan S. Epithelial ovarian cancer: review article. *Cancer Treat Res Commun*. 2022 Sep 8;33:100629.
44. Flores-Balcázar CH, Urías-Arce DM. Radiotherapy in women with epithelial ovarian cancer: historical role, current advances, and indications. *Chin Clin Oncol*. 2020 Aug;9(4):49–49.
45. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer version 2.2023. 2023 Jan.
46. Swift BE, Covens A, Mintsopoulos V, Parra-Herran C, Bernardini MQ, Nofech-Mozes S, et al. The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma. *International Journal of Gynecologic Cancer*. 2022 Apr 4;32(4):525–31.
47. Whalen K. *Lippincott illustrated reviews: pharmacology*. 7th ed. Radhakrishnan R, Feild C, editors. Philadelphia: Wolters Kluwer; 2019.
48. Katzung BG. *Basic & clinical pharmacology*. 15th ed. North America: Mc Graw Education; 2018.
49. Brunton LL, Knollmann BC. *Goodman and Gilman’s the pharmacological basis of therapeutics*. 14th ed. New York: McGraw Hill; 2022.
50. Lawrenti H. Perkembangan imunoterapi untuk kanker. *Cermin Dunia Kedokteran*. 2018;45(8):616–22.

51. Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. *Am J Manag Care*. 2017 Sep;23(14 Suppl):S259–65.
52. Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. *Cancer Treat Res Commun*. 2021;26.
53. Di Liso E. Chemotherapy-induced nausea and vomiting. In: *Suggestions for Addressing Clinical and Non-Clinical Issues in Palliative Care*. IntechOpen; 2021.
54. Majem M, de las Peñas R, Virizueta JA, Cabezón-Gutiérrez L, Cruz P, Lopez-Castro R, et al. SEOM clinical guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021). *Clinical and Translational Oncology*. 2022 Apr 26;24(4):712–23.
55. Ibrahim N, E. Mansour Y, Sulieman A. Antiemetic medications: agents, current research, and future directions. *Int J Pharm Pharm Sci*. 2019 Apr;4(3):7–14.
56. U.S. Department of Health and Human Services. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017.
57. Al-Salloum HF, AL-Harbi HE, Abdelazeem A. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience. *Journal of Oncology Pharmacy Practice*. 2022 Dec 14;107815522211186.
58. National Comprehensive Cancer Network. NCCN clinical practice in oncology: antiemesis version 1.2023. 2023 Apr.
59. Keputusan Menteri Kesehatan RI. Keputusan menteri kesehatan Republik Indonesia nomor HK.01.07/Menkes/659/2017 tentang formularium nasional. Jakarta; 2017.
60. Chan A, Abdullah MM, Ishak WZBW, Ong-Cornel AB, Villalon AH, Kanesvaran R. Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in cancer guidelines for prevention and management of chemotherapy-induced nausea and vomiting in Southeast Asia: a consensus statement. *J Glob Oncol*. 2017 Dec;3(6):801–13.
61. Tefera BB, Getachew M, Kebede B. Evaluation of drug prescription pattern using World Health Organization prescribing indicators in public health facilities found in Ethiopia: systematic reviews and meta-analysis. *J Pharm Policy Pract*. 2021 Dec 19;14(1):31.

62. Fidinillah M. Evaluasi penggunaan obat antiemetika pada pasien kanker serviks di RSUP Dr. Moewardi Surakarta tahun 2018 [Skripsi]. Universitas Muhammadiyah Surakarta; 2018.
63. Tassew SG, Abraha HN, Gidey K, Gebre AK. Assessment of drug use pattern using WHO core drug use indicators in selected general hospitals: a cross-sectional study in Tigray region, Ethiopia. *BMJ Open*. 2021 Oct 27;11(10).
64. Rawal KB, Mateti UV, Shetty V, Shastry CS, Unnikrishnan MK, Shetty S, et al. Development of evidence-based indicators for the detection of drug-related problems among ovarian cancer patients. *Front Pharmacol*. 2023 Jun 30;14.
65. Hanutami B, Lestari K. Identifikasi interaksi antar obat pada resep di Apotek Kimia Farma 58 Kota Bandung. *Jurnal Farmaka*. 2019 Aug 6;17(2):57–64.
66. Adiana S, Maulina D. Klasifikasi permasalahan terkait obat (Drug Related Problem/DRPs): review. *Indonesian Journal of Health Science*. 2022 Jul 18;2(2):54–8.
67. Umar RM. Drug-drug interactions between antiemetics used in cancer patients. *Journal of Oncological Sciences*. 2018 Dec;4(3):142–6.
68. Hardani, Auliya NH, Andriani H, Fardani RA, Ustiawaty J, Utami EF, et al. Buku metode penelitian kualitatif & kuantitatif. 1st ed. Abadi H, editor. Yogyakarta: CV. Pustaka Ilmu Group Yogyakarta; 2020. 359–377 p.
69. Agusweni T, Dewi YI, Erwin E. Gambaran faktor risiko insiden kanker ovarium di RSUD Arifin Achmad Provinsi Riau. *Jurnal Ners Indonesia*. 2020 Sep 30;11(1):36.
70. Kementerian Pemberdayaan Perempuan dan Perlindungan Anak. Profil perempuan Indonesia 2022. 2022 Apr 3;
71. Lawson-Michod KA, Watt MH, Grieshober L, Green SE, Karabegovic L, Derzon S, et al. Pathways to ovarian cancer diagnosis: a qualitative study. *BMC Womens Health*. 2022 Nov 4;22(1):430.
72. Nurmaliza L, Lubis RC. Menarche dini dan gangguan menstruasi pada wanita terhadap kejadian kanker ovarium. *Jurnal Ilmiah Kohesi*. 2023 Jan 18;7(1):61–4.
73. Saki S, Ali NR, Saki SS, AlRabeea ZS, AlRemeithi FN, Carrick FR, et al. Barriers to healthcare seeking, beliefs about ovarian cancer and the role of socio-economic position. a cross-sectional multilevel study in Dubai, a multicultural society. *J Public Health Res*. 2021 Jun 24;10(3):jphr.2021.2073.

74. Raghupathi V, Raghupathi W. The influence of education on health: an empirical assessment of OECD countries for the period 1995–2015. *Archives of Public Health*. 2020 Dec 6;78(1):20.
75. Purwoko M. Hubungan tingkat pendidikan dan pekerjaan dengan tingkat pengetahuan mengenai kanker ovarium pada wanita. *Mutiara Medika: Jurnal Kedokteran dan Kesehatan*. 2018;18(2):45–8.
76. Shin W, Jeong G, Son Y, Seo SS, Kang S, Park SY, et al. The knowledge and attitude of patients diagnosed with epithelial ovarian cancer towards genetic testing. *Int J Environ Res Public Health*. 2021 Feb 26;18(5):2312.
77. Rizvi Z, Sharma KC, Kunder V, Abreu A. Barriers of care to ovarian cancer: a scoping review. *Cureus*. 2023 Jun 12;
78. Dewi TP, Indriyani F, Nasution RF. Hubungan usia dengan patologi anatomi pada kanker ovarium di Rumah Sakit Umum Dr. Zainoel Abidin periode September 2020- September 2022. *Jurnal Kedokteran Syiah Kuala*. 2023 Mar;23(1):16–23.
79. Mulyana Hidayat Y, Febe Febriani E, Budi Harsono A, N. A. Winarno G, Kurniadi A. Karakteristik karsinoma ovarium pra-menopause dengan kadar CA 125 \leq 200 U/mL di RSUP Dr. Hasan Sadikin Bandung dari tahun 2019–2021. *Indonesian Journal of Obstetrics & Gynecology Science*. 2023 Jul 17;6(2):263–70.
80. Kaplan V. Mental health states of housewives: an evaluation in terms of self-perception and codependency. *Int J Ment Health Addict*. 2023 Feb 6;21(1):666–83.
81. Friesen MC, Beane Freeman LE. Identifying occupational risk factors for cancer in women: a need for further action. *Occup Environ Med*. 2023 Sep;80(9):522–3.
82. Gwacham NI, Ahmad S. Introduction to gynecologic cancers: emphasis on pathogenesis, incidence, and diagnosis. In: *Overcoming Drug Resistance in Gynecologic Cancers*. 1st ed. Elsevier; 2021. p. 1–22.
83. Dakeng S, Porntadavity S, Patmasiriwat P. BRCA1 and TP53 mutations in ovarian cancer: molecular genetic insights and updated situations in Thailand. *Genomics and Genetics*. 2018 Dec 28;11(3):26–35.
84. Tandarto M, Ginting E, Nuryanto MK. Hubungan usia menarche dengan kejadian kanker ovarium. *Husada Mahakam: Jurnal Kesehatan*. 2020 Jun 4;10(1):71–7.
85. Simamora RPA, Hanriko R, Sari RDP. Hubungan usia, jumlah paritas, dan usia menarche terhadap derajat histopatologi kanker ovarium di RSUD Dr. H. Abdul Moeloek Bandar Lampung tahun 2015-2016. *Medical Journal of Lampung University*. 2018 Mar;7(2):7–13.

86. Chung WM, Chen L, Chang WC, Su SY, Hung YC, Ma WL. Androgen/Androgen receptor signaling in ovarian cancer: molecular regulation and therapeutic potentials. *Int J Mol Sci.* 2021 Jul 20;22(14):7748.
87. Aqilla S, Harsono AB, Agustina H. Gambaran klinis dan histopatologi kanker ovarium di RSUP Dr. Hasan Sadikin Bandung tahun 2019-2020. *Indonesian Journal of Obstetrics & Gynecology Science.* 2022 Mar 28;5(1):127–35.
88. Khanlarkhani N, Azizi E, Amidi F, Khodarahmian M, Salehi E, Pazhohan A, et al. Metabolic risk factors of ovarian cancer: a review. *JBRA Assist Reprod.* 2021 Apr 17;17(26):335–47.
89. Oh H, Wild RA, Manson JE, Bea JW, Shadyab AH, Pfeiffer RM, et al. Obesity, height, and serum androgen metabolism among postmenopausal women in the women's health initiative observational study. *Cancer Epidemiology, Biomarkers & Prevention.* 2021 Nov 1;30(11):2018–29.
90. Ellwanger B, Schöler-Toprak S, Jochem C, Leitzmann MF, Baurecht H. Anthropometric factors and the risk of ovarian cancer: a systematic review and meta-analysis. *Cancer Rep.* 2022 Nov 5;5(11).
91. Avramenko AS, Flanagan JM. An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use. *Clin Epigenetics.* 2023 Oct 18;15(1):165.
92. Koziel MJ, Piastowska-Ciesielska AW. Estrogens, estrogen receptors and tumor microenvironment in ovarian cancer. *Int J Mol Sci.* 2023 Sep 28;24(19):14673.
93. Wenang S, Dhiya AN A, Pratiwi WA, Lelle RJ, Haier J. Risk factors of ovarian cancer in PKU Muhammadiyah Teaching Hospital Yogyakarta. *Mutiara Medika: Jurnal Kedokteran dan Kesehatan.* 2020 Jul;20(2):62–6.
94. Oktafiani E. Analisis biaya riil dan kesesuaian dengan tarif INA-CBGs pada pasien kanker ovarium Di RSUD Dr. Moewardi Surakarta tahun 2018. *Jurnal Farmasi Indonesia.* 2020 Nov 30;17(2):156–65.
95. Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. *Front Pharmacol.* 2023 May 9;14.
96. Punneshetty S, Sebastian A, Thomas V, Daniel S, Briskala P, Singh A, et al. Malignant metastatic steroid cell tumor nos: a rare presentation of a subtype of sex cord stromal tumor. *Gynecol Oncol Rep.* 2023 Apr;46:101169.
97. Li J, Li J, Jiang W. Oncological prognosis and fertility outcomes of different surgical extents for malignant ovarian sex-cord stromal tumors: a narrative review. *Cancer Manag Res.* 2022 Feb;14:697–717.

98. Kusumawardani EEY. Evaluasi penatalaksanaan mual muntah pasca kemoterapi pada pasien kanker serviks di Rumah Sakit Umum Pusat Dr. Kariadi Semarang periode 2019 [Skripsi]. [Semarang]: Universitas Islam Sultan Agung; 2021.
99. Shaveta S, Diksha C, Puneet S, Upendra JK. Short review on domperidone tablet. *Journal of Applied Pharmaceutical Research* . 2017 Mar;5(1):14–9.
100. Fauziah Hasdin, Dinda Monika, Bambang Subakti. Review article: mechanisms and efficacy of using diphenhydramine as a chemotherapy premedication. *J Pharm Negat Results*. 2022 Oct 13;13(6):2268–76.
101. Simbolon PDH, Nafianti S, Sianturi P, Lubis B, Lelo A. The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients. *Paediatr Indones*. 2018 Mar 20;58(1):42–7.
102. Firdaus NZ, Susilowati S. Evaluasi penggunaan kemoterapi pada pasien kanker payudara di Rumah Sakit Islam Sultan Agung Semarang periode 2022. *Jurnal Ilmu Farmasi dan Farmasi Klinik*. 2023 Dec 28;20(2):155–66.
103. Herrstedt J, Lindberg S, Petersen PC. Prevention of chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes. *Drugs Aging*. 2022 Jan 9;39(1):1–21.
104. Rahmadi M, Kharismawati ID, Purwanto H, Harini I, Suharjono S, Alderman C. Analysis of antiemetic premedication administration timing on nausea and vomiting incidence among breast cancer patients receiving chemotherapy. *Indonesian Journal of Clinical Pharmacy*. 2020 Dec 10;9(4):298.
105. Warr D. Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice. *Supportive Care in Cancer*. 2018 Mar 19;26(1):29–33.
106. Merrow M, King N. Optimizing antiemetic therapy for children undergoing chemotherapy. *J Pediatr Nurs*. 2022 Jul 24;66:136–42.
107. Gu YL, Xie J ming, Ren J, Cao H, Wei J rong, Chen C, et al. Dexamethasone-sparing regimen is an effective and safe alternative in overall antiemetic protection. *Medicine*. 2019 Sep 27;98(39):e17364.
108. Ariyani AF, Purmayanti A, Kirtishanti A. Efektivitas ondansetron sebagai profilaksis mual dan muntah pada pasien kanker payudara stadium 3 pasca kemoterapi. *Journal of Islamic Pharmacy*. 2022 Jun;7(1):41–5.
109. Efmisa AK, Armenia A, Almasdy D. Penggunaan obat hepatotoksik pada pasien sirosis hati: review artikel. *Journal of Pharmaceutical and Sciences*. 2023 Jun 26;6(2):766–71.

110. Rahayuningsih N, Nurfatwa M, Idacahyati K. An overview of potential drug interactions in patients with cesarean section at RSUD Dr. Soekardjo Tasikmalaya. *J Phys Conf Ser.* 2019 Jul 1;1179(1):012124.

